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Abstract
Background: In 1996, Mexico started to register cases of childhood cancer. Here, we describe the incidence of cancer
in children, residing in ten Mexican jurisdictions, who were treated by the Instituto Mexicano del Seguro Social (IMSS).
Methods: New cases of childhood cancer, which were registered prospectively in nine principal Medical Centers of IMSS
during the periods 1998–2000 (five jurisdictions) and 1996–2002 (five jurisdictions), were analyzed. Personnel were
specifically trained to register, capture, and encode information. For each of these jurisdictions, the frequency, average
annual age-standardized incidence (AAS) and average annual incidence per period by sex and, age, were calculated (rates
per 1,000,000 children/years).
Results: In total 2,615 new cases of cancer were registered, with the male/female ratio generally >1, but in some tumors
there were more cases in females (retinoblastoma, germ cells tumors). The principal groups of neoplasms in seven
jurisdictions were leukemias, central nervous system tumors (CNS tumors), and lymphomas, and the combined
frequency for these three groups was 62.6 to 77.2%. Most frequently found (five jurisdictions) was the North American-
European pattern (leukemias-CNS tumors-lymphomas). Eight jurisdictions had AAS within the range reported in the
world literature. The highest incidence was found for children underless than five year of age. In eight jurisdictions,
leukemia had high incidence (>50). The AAS of lymphomas was between 1.9 to 28.6. Chiapas and Guerrero had the
highest AAS of CNS tumors (31.9 and 30.3, respectively). The frequency and incidence of neuroblastoma was low.
Chiapas had the highest incidence of retinoblastoma (21.8). Germ-cell tumors had high incidence.
Conclusion: The North American-European pattern of cancers was the principal one found; the overall incidence was
within the range reported worldwide. In general but particularly in two jurisdictions (Yucatán and Chiapas), it will be
necessary to carry out studies concerning the causes of cancer in children. Due to the little that is known about the
incidence of cancer in Mexican children, it will be necessary to develop a national program to establish a cancer registry
for the whole of the country.
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Background
Cancer in children differs from that in adults. In general,
the principal groups of cancer in children are leukemias,
lymphomas, and sarcomas, whereas in adults, the chief
cancers are carcinomas [1]. For this reason, the manner of
grouping the cancers for study is different. For children,
the International Classification of Childhood Cancer
(ICCC) is used; it is based on the morphology of the
tumors and is composed of 12 main groups [2].
Childhood cancer encompasses, in general, the cases of
cancer found in the cohort of 0–14 year-old children;
however, some registers also include those found in the
15–19 year-old cohort [3]. At present, there is a contro-
versy regarding the interpretation of trends because
researchers in the United States of America (USA) and
France [4,5] have shown no increase, whereas other
researchers in Europe have shown an increase, in general,
for acute lymphoblastic leukemia, Hodgkin's disease, cen-
tral nervous system tumors (CNS tumors), and germ cell
tumors [6-9]. Likewise, other investigators in the USA
have demonstrated that there is a trend toward increase in
the 0–9 year-old group [10].
Worldwide, the incidence of childhood cancer is generally
between 100–180 per 1,000,000 children/year [11]. How-
ever, the incidence of the principal groups of cancers dif-
fers according to the country in which the study took
place: For example, in the USA, the incidence of leukemia
is 47.8 per 1,000,000 children/year [4], whereas in some
countries, it can reach as high as 57.9 per 1,000,000 chil-
dren/year [11]. Therefore, based on the three principal
groups of cancer, various patterns of presentation of the
disease have been described: 1) North American-Euro-
pean pattern (1st, leukemias; 2nd, CNS tumors; and 3rd,
lymphomas); 2) Latin American pattern (1st, leukemias;
2nd, lymphomas; and 3rd, CNS tumors); and 3) African
pattern (1st, lymphomas; 2nd, leukemias; and 3rd, CNS
tumors or soft tissue sarcomas) [12].
By sex, the male/female ratio (M/F) is generally 1.2, but
this value may vary according to country and to the type
of cancer. For example, in many countries, the M/F for
leukemias is 1.3; for Hodgkin lymphomas (HL), 2.5 or
higher; and for renal tumors (Wilms tumor), <1. By age,
the highest incidence of neoplasms in general is found in
children less than five years old [12].
Other aspects of great relevance for the descriptive epide-
miology of childhood cancer may be noted, such as the
incidence in relation to environment (urban/rural), race,
occupation of the parents, socio-economic stratum
[12,13]. However, what should be most evident is that all
these data are obtained, in general, from population-
based cancer registries [3,5-9,11].
Due to the lack of a national program for the registry of
childhood cancer, in Mexico data exist only for the inci-
dence of cancer in those children who reside in Mexico
City and who are entitled to treatment by the Instituto
Mexicano del Seguro Social (IMSS). These data are
obtained by means of hospital surveys. In other jurisdic-
tions in the country, only the frequency of those cases
treated in some hospitals is known, but the incidence is
not known due to the absence of a specific registry for can-
cer and to the difficulties in obtaining the population at
risk (denominators) [14-16]. This situation results in a
grave problem, in that the magnitude of the problem of
childhood cancer in the greater part of the jurisdictions of
the country is unknown.
The aim of the present study is to present the incidence
rates and the main groups of cancer in those children in
ten jurisdictions of the Mexican Republic, who were
treated by IMSS. IMSS is the principal institution that pro-
vides medical attention in Mexico, serving 50% of the
population of the country. Socio-economic distinctions
exist between the jurisdictions, which are reflected in their
populations.
Methods
Type of study
Population-based, prospective study.
Sources of information
IMSS provides medical attention to workers and their
families. When a child of a worker develops some form of
cancer, the child is sent to one of the specialized hospitals
in the IMSS system (Medical Center-IMSS), which are dis-
tributed strategically throughout the country. The Medical
Centers-IMSS are hospitals that have both the specialized
personnel (oncologists, surgeons, hematologists, and
pediatric pathologists) and the technology necessary to
perform precise diagnosis and to give the treatment
required for a child with cancer. IMSS keeps a register of
the population entitled to receive medical attention at its
facilities; therefore, the base population is known and it is
feasible to obtain the incidence rate for the population
under 15 years of age (Table 1). Not only do children with
cancer receive medical treatment at no cost, but also when
such children reside in areas in which no Medical Center-
IMSS is located, they are referred to a Medical Center-IMSS
closest to their place of residence, with IMSS covering the
cost of transportation of these children for treatment.
The information for this study was taken from two differ-
ent sources of data. The first was the Registry of Child-
hood Cancer that was established in the Unit of Medical
Research in Clinical Epidemiology of the Pediatric Hospi-
tal of the National Medical Center "Siglo XXI" of IMSS.
This population-based registry of cases of cancer wasBMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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started in 1996 and is ongoing [17]. Cases are registered
for those children who are treated in Mexico City in either
of the two hospitals, the Pediatric Hospital of the National
Medical Center "Siglo XXI" and the General Hospital of
the National Medical Center "La Raza", that IMSS main-
tains for providing free medical attention to those who, by
right of being residents of Mexico City, are entitled to its
services. These hospitals also treat children with cancer
who are referred from other states of the Mexican Repub-
lic. The data were collected prospectively. Thus, the data
used in this study represent the new cases of children with
cancer, during the period 1996–2002, from Mexico City
and from four states (Mexico, Morelos, Guerrero, and Chi-
apas), the first two located in the center of the country and
last two, in the south (see Figure 1).
The second source of data was a hospital survey carried
out during the period 1998–2000 in the remaining five
Medical Centers-IMSS: one in the north of Mexico (Nuevo
León); one in the west (Jalisco); one in the central part of
the country (Puebla); one in the east (Veracruz); and one
in the southeast (Yucatán) (see Figure 1). It should be
noted that, in general, the populations in these jurisdic-
tions are socio-economically distinct: Those in the North,
West, Center, and East of the country are richer, whereas
those in the South are poorer.
Because it is indispensable for providing treatment of any
kind, the diagnosis of cancer for each patient who was
included in the study, from both sources of data, was con-
firmed either by aspiration of bone marrow in the cases of
leukemia or by histopathological study of the tumors for
the remaining cases of different cancers. Only one patient,
suspected of having hepatoblastoma, received chemother-
apy without having had the diagnosis confirmed by
biopsy. Unfortunately, the child died and a postmortem
study was not done; however, the case was included in the
analysis. For this reason, we consider that the histopatho-
logical validation of the registered cases was practically
100%.
Study population
Numerators
The cases included in the numerators were those of
patients who were treated at the different Medical Center-
IMSS and who were residents in the above-mentioned
jurisdictions. Only new cancer cases for children less than
15 years of age were included; prevalent cancer cases were
excluded.
Denominators
IMSS holds a very precise record of the population enti-
tled to receive medical care in its facilities; therefore, the
population under 15 years of age and residing in the dif-
ferent jurisdictions during the period studied, the value
needed to calculate the incidence, was obtained from the
Coordination of Medical Treatment of the Medical
Financing Board of IMSS. This is the only governmental
agency that calculates all the populations with access to
medical attention provided by the IMSS [18]. This infor-
mation is updated every year by the IMSS. The recorded
population of each of the jurisdictions during the study
periods is shown in Table 1.
Hospital units from which data were obtained
A child with cancer might be treated in different hospital
services; therefore, the data were obtained from various
pediatric services (Oncology, Hematology, Surgery, Neu-
rosurgery, Endocrinology) of the different Medical Cent-
ers-IMSS selected, all of which have the infrastructure
(well-trained personnel and technology) necessary to
establish the diagnosis of malignant neoplasia precisely.
Variables of the study
Prior to carrying out the study, we designed a form listing
the variables of interest: those of the individual (e.g., sex,
Table 1: Population at risk of children served by IMSS and assigned a family doctor in ten jurisdictions of the Mexican Republic during 
the study periods
Age group (years) Sex
Jurisdictions Periods <1 1 – 4 5 – 9 10 – 14 0 – 14 Male Female
Chiapas 1996–2002 36 291 186 336 272 335 248 197 743 159 375 498 367 661
México City " 375 761 1 597 012 2 049 305 1 907 323 5 929 401 3 024 225 2 905 176
Guerrero " 38 352 206 442 282 347 221 690 748 831 378 945 369 886
México State " 463 520 1 962 182 2 538 935 2 298 797 7 263 434 3 693 756 3 569 678
Morelos " 38 281 218 981 284 204 249 268 790 734 404 759 385 975
Jalisco 1998–2000 138 929 656 340 799 563 718 287 2 313 119 1 180 648 1 132 471
Nuevo León " 129 612 522 439 592 491 490 141 1 734 683 885 697 848 986
Puebla " 36 580 219 003 281 628 244 852 782 063 397 323 384 740
Veracruz " 48 841 282 157 400 989 378 902 1 110 889 566 340 544 549
Yucatán " 27 506 149 060 181 721 154 519 512 806 261 102 251 704
Source: Coordinación de Atención Médica. Estructura de Población Adscrita a Médico Familiar, 1996–2002. Instituto Mexicano del Seguro Social, 
México (Reference 18).BMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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age at diagnosis, type of neoplasm), of place (residence
according to the districts in which the Medical Centers-
IMSS are located in the ten jurisdictions included in this
study), and of time (age at diagnosis). All the foregoing
variables were obtained by interviewing the parents or by
reviewing the respective clinical records; such information
was obtained for 100% of the cases included in this study.
Procedure for obtaining, encoding, and validating the 
information
Prior to the actual gathering of data, nurses whose job it
would be to collect and code such data, were specifically
trained not only in obtaining the appropriate information
from the hospital, but also in registering, coding, and ver-
ifying the type of cancer, site, and diagnosis of the cancer
for each patient. In a pilot test at the last stage of the train-
ing, these nurses showed a good consistency in their cod-
ing of the data (unweighted Kappa = 0.85). However, the
final encoding of the cases from both sources of data was
carried out by personnel (three physicians and two
nurses) of the Registry of Childhood Cancer of the Unit of
Medical Research in Clinical Epidemiology of the Pediat-
ric Hospital of the National Medical Center "Siglo XXI" of
IMSS, all of whom had also been trained in the registry
and coding of cases of cancer and who had shown an ade-
quate consistency in coding the morphology, topography,
and staging of the different cancers (unweighted Kappa =
0.90).
Therefore, for each of the nine Medical Centers-IMSS
selected, a nurse was assigned to register all the new cases
of malignant neoplasms in children. These nurses went
every third day to the above-mentioned hospital services,
with the aim of capturing all possible new cases of cancer.
The nurse registered this information in a special file and
then used the questionnaire to obtain pertinent informa-
tion from the parents, which was needed for the study.
Once a diagnosis of cancer had been confirmed, the nurse
captured the data for inclusion in this study; those diag-
noses not confirmed were discarded. If for any reason the
Jurisdictions of the Mexican Republic included in the study Figure 1
Jurisdictions of the Mexican Republic included in the study.BMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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patient had been released from the hospital, the nurse
reviewed the patient's medical record in the archives of
the respective hospital to learn the final diagnosis.
To encode the different cases of cancer, topographic and
morphological coding was used; for the cases collected
between 1996 through 1999, the second edition of the
"International Classification of Diseases for Oncology"
(ICD-O-2) was used, and for the cases between 2000
through 2002, the third edition (ICD-O-3) [19,20].
The collected information was then captured on two occa-
sions with the aim of detecting any problems in capturing
the data and, prior to analysis of the data, the respective
databases were reviewed in search of duplicated cases and
missing data.
Also, validation of the principal variables of the study
(morphology and topography of the different types of
cancer; age; sex) was performed by using the program,
Child-Check, that was developed by the International
Agency for Research on Cancer (IARC) [21], which evalu-
ates the internal consistency of the individual cancer reg-
istries. The different types of cancer were grouped
according to the ICCC [2].
Case completeness
With the aim of having an objective evaluation of the case
completeness in the different Jurisdictions included in the
study, the expected incidence was calculated. To this end,
we used the method that the North American Association
of Central Cancer Registries follows to evaluate the case
completeness when evaluating a central registry [22]. In
this method, the ratio between the rate of the incidence of
cancer and the mortality rate of cancer is calculated; there-
fore, the values not only of the incidence, but also of the
mortality, must be as precise as is possible. The incidence
(126.4 per million children/year) that we used was that of
the jurisdiction of Mexico City and the mortality (71.7 per
million children/year) was that reported by IMSS for chil-
dren (0 to 14 years) during the period 1995–2000 [23].
With these data, we obtained the ratio for these rates
(1.76) and we multiplied this value by the mortality for
the period 1995–2000 that had been reported for each
jurisdiction studied [23]. By using this method, we found
that, in nine jurisdictions, the ratio of the observed/
expected rates was equal to, or greater than 0.90; only in
Jalisco, was it 0.71 (data not shown).
Analysis
The absolute and the relative frequencies were obtained
according to the type of neoplasm, to sex, and to age, with
age being stratified into four subgroups (less then one
year of age, one to four year-olds, five to nine year-olds,
and ten to 14 year-olds). For each of the periods under
study (1996–2002 and 1998–2000), the average annual
age-standardized incidence (AAS) per period, both gen-
eral and that for the different neoplasms grouped accord-
ing to ICCC, were calculated by using the direct method
and by taking the standard world population under 15
years of age as reference population [24]. Also calculated
was the incidence according to sex, age, and place of resi-
dence for the selected jurisdictions of the Mexican Repub-
lic; the rates are given per 1,000,000 children/year. The
protocol was approved by the Research and Ethics Coor-
dination of the Pediatric Hospital, National Medical
Center Century XXI, Instituto Mexicano del Seguro Social.
Results
A total of 2,615 new cases of cancer in children was regis-
tered, of which 1,957 (74.8%) corresponded to the period
1996–2002 in the Pediatric Hospital of Medical Center
"Siglo XXI" and Medical Center of "La Raza" (both in
Mexico City) and 658 (25.2%) for the period 1998–2000
in the remaining Medical Centers. Table 2 shows the dif-
ferent types of neoplasms that were registered in each of
the ten jurisdictions. Of the total number of cases in the
study, 1,572 (60.1%) came from either Mexico City or the
State of Mexico.
In general, the three types of neoplasms most commonly
found were leukemias, with frequencies between 31.6%
(Nuevo León) and 51.4% (Mexico State); CNS tumors,
with frequencies between 8.8% (Puebla) and 18.6%
(Nuevo León); and lymphomas, with frequencies
between 2.0% (Yucatán) and 16.8%, (Guerrero). Only in
Jalisco did CNS tumors and bone tumors have the same
frequency (10.5%); in Yucatán, CNS tumors and germ cell
tumors had the same frequency (9.8%) (Table 2).
As to specific type of neoplasms, among leukemias, acute
lymphoblastic predominated; among lymphomas, non-
Hodgkin (non-HL) predominated in six jurisdictions, and
HL, in five; among CNS tumors, astrocytomas predomi-
nated in nine jurisdictions; between tumors of the sympa-
thetic nervous system, neuroblastoma; between renal
tumors, nephroblastoma; between hepatic tumors, hepa-
toblastoma; among bone tumors, osteosarcoma; among
soft tissue sarcomas, rabdomyosarcoma predominated in
six jurisdictions; and among germ cell tumors, malignant
gonadal tumors. Due to the low frequency of carcinomas,
it was difficult to establish with precision which type had
the highest frequency (Table 2).
The AAS was found to range between 83.6 (Jalisco) and
203.5 (Chiapas). Notably, leukemias had the highest inci-
dence in Chiapas (74.2); HL, in Puebla (11.9); non-HL, in
Guerrero (19.9); CNS tumors, in Chiapas (31.9); neurob-
lastoma, in Guerrero (13.5); retinoblastoma, in Chiapas
(21.8); renal tumors, in Morelos (10.8); hepatic tumors,B
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Table 2: Frequency of cancer in children served by the IMSS and residing in ten jurisdictions of the Mexican Republic during the periods 1996–2002 and 1998–2000
Diagnostic Group 1996–2002 1998–2000
CHIS MC GRO MS MOR JAL NL PUE VER YUC Overall
n%n%n%n%n%n%n%n%n% n % n %
I. Leukemias 54 37.8 321 43.7 43 34.4 431 51.4 54 46.2 97 50.8 56 31.6 56 49.1 60 48.0 25 49.0 1197 45.81
+ Acute lymphoblastic 37 68.5 249 77.6 35 81.4 352 81.7 42 77.7 78 80.3 53 94.6 48 85.7 46 76.7 18 72.0 958 80.02
+ Acute non-lymphoblastic 16 29.6 58 18.1 7 16.3 70 16.3 12 22.3 16 16.5 3 5.4 8 14.3 11 18.3 5 20.0 206 17.2
II. Lymphomas3 15 10.5 88 12.0 21 16.8 75 9.0 15 12.9 17 8.9 22 12.4 19 16.7 16 12.8 1 2.0 289 11.1
+ Hodgkin lymphomas 6 40.0 23 25.9 7 33.3 36 47.8 3 20.2 6 34.8 10 45.2 10 52.7 9 56.3 1 100.0 111 38.4
+ Non Hodgkin lymphomas 7 46.7 53 60.4 9 42.9 35 46.7 9 59.7 7 41.6 8 36.3 8 41.9 4 25.0 0 0.0 140 48.4
+ Burkitt lymphoma 2 13.3 9 10.3 5 23.8 3 4.4 3 20.2 4 23.6 3 13.7 1 5.4 3 18.8 0 0.0 33 11.4
III. CNS tumors 21 14.7 98 13.4 23 18.4 75 9.0 11 9.5 20 10.5 33 18.6 10 8.8 19 15.2 5 9.8 315 12.0
+ Ependymomas 3 14.3 14 14.2 3 13.0 10 13.3 1 9.5 1 4.9 2 5.9 0 0.0 4 21.1 0 0.0 38 12.1
+ Astrocytomas 9 42.9 52 53.0 13 56.5 31 41.1 5 45.3 5 24.8 14 42.5 4 39.8 5 26.3 1 20.4 139 44.1
+ IIET 5 23.8 25 25.4 6 26.1 25 33.3 3 27.4 4 20.3 12 36.6 1 10.2 5 26.3 2 39.8 88 27.9
IV. Neuroblastoma and others 3 2.1 22 3.0 8 6.4 16 1.9 2 1.7 4 2.1 11 6.2 1 0.9 1 0.8 3 5.9 71 2.7
+ Neuroblastoma 3 100.0 21 96.7 8 100.0 14 89.5 2 100.0 4 100.0 10 90.3 1 100.0 1 100.0 3 100.0 66 93.0
V. Retinoblastoma 12 8.4 26 3.5 5 4.0 33 3.9 6 5.1 3 1.6 7 4.0 4 3.5 6 4.8 3 5.9 105 4.0
VI. Renal tumors 4 2.8 30 4.1 7 5.6 33 4.0 7 6.0 5 2.6 10 5.6 2 1.8 6 4.8 2 3.9 106 4.1
+ Nephroblastoma 4 100.0 28 97.5 7 100.0 33 100.0 7 100.0 5 100.0 10 100.0 2 100.0 6 100.0 2 100.0 105 99.1
VII. Hepatic tumors 3 2.1 19 2.6 0 0.0 10 1.2 1 0.9 4 2.1 3 1.7 6 5.3 1 0.8 1 2.0 48 1.8
+ Hepatoblastoma 2 66.7 17 88.5 0 0.0 9 91.7 1 100.0 4 100.0 3 100.0 6 100.0 1 100.0 1 100.0 44 91.7
VIII. Bone tumors 10 7.0 39 5.3 8 6.4 47 5.6 7 6.0 20 10.5 5 2.8 5 4.4 3 2.4 4 7.8 148 5.7
+ Osteosarcomas 8 80.0 27 70.0 5 62.5 36 76.8 4 56.7 19 94.9 4 80.0 3 59.1 2 66.7 2 50.0 110 74.3
IX. Soft tissue sarcomas 9 6.3 41 5.6 6 4.8 44 5.3 7 6.0 13 6.8 14 7.9 5 4.4 4 3.2 2 3.9 145 5.5
+ Rhabdomyosarcomas 4 44.4 25 61.2 1 16.7 27 60.4 4 56.7 8 61.8 12 85.4 2 40.9 4 100.0 1 50.0 88 60.7
+ Fibrosarcomas 4 44.4 9 21.9 1 16.7 8 18.9 1 15.0 0 0.0 1 7.3 0 0.0 0 0.0 0 0.0 24 16.6
X. Germ cell tumors 7 4.9 45 6.1 2 1.6 67 8.0 5 4.3 7 3.7 14 7.9 6 5.3 9 7.2 5 9.8 167 6.4
+ Malignant gonadal 4 57.1 35 77.8 2 100.0 49 72.5 2 39.5 3 43.2 10 70.9 4 66.0 4 44.4 4 79.6 117 70.1
XI. Carcinomas 5 3.5 5 0.7 2 1.6 7 0.7 2 1.7 1 0.5 2 1.1 0 0.0 0 0.0 0 0.0 24 0.9
TOTAL 143 100 734 100 125 100 838 100 117 100 191 100 177 100 114 100 125 100 51 100 2615 100
1Intergroup frequency (%); 2Intragroup frequency (%), only the frequencies of principal subgroups are presented; 363 cases of Histiocytosis were not included; IMSS, Instituto Mexicano del Seguro Social; n, 
Number of cases; CNS, Central Nervous System; IIET, Intracraneal and Intraespinal Embryonal Tumors; CHIS, Chiapas; MC, Mexico City; GRO, Guerrero; MS, Mexico State; MOR, Morelos; JAL, Jalisco; NL, 
Nuevo León; PUE, Puebla; VER, Veracurz; YUC, Yucatán.BMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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in Puebla (11.3); bone tumors (12.2), soft tissue sarcomas
(14.0), and carcinomas (5.9), all highest in Chiapas; and
germ cell tumors, in Yucatán (10.6) (Table 3).
In general, the M/F ratio was higher than 1, with it being
highest (1.4) in Jalisco; only in Yucatán was it less than 1.
However, a greater variation in the M/F ratio was found
within the different groups of neoplasms (Tables 4, 5, 6).
By age, the incidence for those <1 year of age varied
between 38.6 and 330.7, with the highest found in the
states of Chiapas, Puebla, and Morelos (330.7, 300.7, and
235.1, respectively); for 1–4 year-olds, the incidence var-
ied between 106.7 and 263.0. The incidence was lower for
5–9 year-olds, ranging between 63.8 and 143.2, but rose
again for 10–14 year-olds, varying between 82.1 and
173.2 (Tables 4, 5, 6).
In regard to the principal pattern of presentation, the
North American-European pattern (1st, leukemias; 2nd,
CNS tumors; and 3rd, lymphomas) was found in five juris-
dictions; the Latin American pattern (1st, leukemias; 2nd,
lymphomas; and 3rd, CNS tumors) in two jurisdictions;
and in the other three jurisdictions, although leukemias
and CNS tumors were predominant, bone tumors, germ
cell tumors, or retinoblastoma were in second or third
place (Jalisco, Yucatán, and Chiapas, respectively) (Tables
4, 5, 6).
Discussion
A better understanding both of the descriptive epidemiol-
ogy and of the underlying causes of childhood cancer
would greatly aid the medical community and health
authorities in Mexico to improve treatment for one of the
most vulnerable populations, that of infants and children.
Registering cases of cancer in children can be an enor-
mous aid in understanding the epidemiology of these dis-
eases. But it must be kept in mind that, to improve the
precision of the estimates, it is necessary not only to have
a completeness of coverage of cases, but also to have a
quality control in an appropriate form in which to collect
and register the data [22].
The quality should be evaluated in relation not only to the
manner in which the data were collected but also, when a
register is based on information obtained in the hospitals
treating the children, to the rigorousness of the search for
these cases in the different hospital services. Because cases
so detected comprise the numerator for the estimation of
the incidence rates, it has been recommended that medi-
cal records be reviewed in all those departments or serv-
ices (e.g., Oncology, Hematology, Surgery,
Endocrinology, Neurosurgery, Pathology, and Radiother-
apy), in which medical attention may have been provided
to a child with cancer and in which, therefore, a case of
childhood cancer may have been registered [22]. Thus, for
this study, the participating nurses searched exhaustively
in these various hospital services for possible cases and
performed a detailed registry of such information.
Another fundamental aspect is the reference population
(or, the population at risk) from which the cases were
taken. Because IMSS keeps a rigorous registry both of
those entitled to treatment and of those treated in its facil-
ities, the precise numbers of the populations that com-
prise the denominators needed to estimate the rates of
incidence were obtained (Table 1) [18].
Because a population-based cancer registry is the "gold
standard" for ascertaining the number of cancer cases that
develops within a population, it is very difficult to evalu-
ate if this ascertainment is complete. Children with cancer
must be treated in specialized medical units and, at IMSS,
they are treated in the Medical Centers-IMSS, because
such centers have the necessary infrastructure and the
medical personnel dedicated to the specialized treatment
that children with cancer need. For this reason, we
decided to select these centers to carry out this study.
Additionally, the personnel that participated in the collec-
tion of data performed a strict inquiry into the number of
new cases presented in the selected hospitals. We think
that, through these actions, over 90% of the new cases that
had developed in the selected jurisdictions were, in fact,
registered. To support this, it was necessary that we had a
proxy with which to assess the validity of the information
registered. An indirect form of so doing was to compare
the incidence rates obtained with those reported world-
wide. For eight of the jurisdictions studied, the exceptions
being Chiapas and Jalisco, the incidence was within the
range of variability (100 to 180 per 1,000,000 children/
year) reported in the world literature [11].
The incidence in Chiapas was higher than that reported
worldwide. In theory, the contrary would have been
expected, because it is more common to underestimate
data for the numerator due to under-diagnosis and/or
under-registration (or under-reporting) of cases. Thus, an
incidence <100 per 1,000,000 children/year, as was found
for Jalisco (82.6 per 1,000,000 children/year), would have
been expected. Jalisco is an state in which, despite our best
efforts to collect all the cases, an underestimation might
be suspected. This situation can be remedied by carrying
out further studies ex profeso or through the establishment
of a Registry of Childhood Cancer in those states where no
such Registry presently exists. Thus, at first glance, the
high value for Chiapas may be thought to have resulted
from the denominator having been underestimated.
However, two factors led us to consider otherwise: Prior
studies have demonstrated a high frequency of cancers,
such as retinoblastoma, in Chiapas [16,25,26], and theBMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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Table 3: Average annual age-standardized incidence per period1 of malignant neoplasms in children served by the IMSS and residing in 
ten jurisdictions of the Mexican Republic during the periods 1996–2002 and 1998–2000
Diagnostic group 1996–2002 1998–2000 Overall
CHIS MC GRO MS MOR JAL NL PUE VER YUC Crude ASR
I. Leukemias 74.2 55.4 58.8 60.2 66.8 42.5 32.5 72.9 54.8 50.1 54.6 55.4
+ Acute lymphoblastic 51.8 43.2 47.3 49.3 52.5 34.3 30.7 62.3 42.6 35.8 43.7 44.52
+ Acute non-lymphoblastic 21.2 9.8 10.1 9.6 14.3 6.8 1.8 10.6 8.9 9.7 9.4 9.3
II. Lymphomas3 18.6 14.4 28.6 9.9 18.9 7.2 12.7 22.7 12.9 1.9 13.2 12.8
+ Hodgkin lymphomas 8.0 3.6 8.6 4.6 3.7 2.5 5.8 11.9 7.4 1.9 5.1 4.8
+ Non Hodgkin lymphomas 8.3 8.9 12.8 4.7 11.1 3.0 4.6 9.4 3.2 0.0 6.4 6.3
+ Burkitt lymphoma 2.4 1.4 7.1 0.4 3.9 1.7 1.7 1.4 2.4 0.0 1.5 1.5
III. CNS tumors 31.9 16.5 30.3 10.3 15.7 8.9 19.2 12.1 16.8 9.5 14.4 14.4
+ Ependymomas 5.4 2.4 4.3 1.4 1.2 0.5 1.2 0.0 3.5 0.0 1.7 1.8
+ Astrocytomas 12.5 8.8 16.2 4.1 7.4 2.3 8.2 5.2 4.6 1.8 6.3 6.3
+ IIET 7.8 4.2 8.3 3.5 3.9 2.0 7.1 1.2 4.6 3.8 4.0 4.1
IV. Neuroblastoma and others 5.5 4.1 13.5 2.4 4.0 1.9 6.5 1.2 0.8 6.2 3.2 3.6
+ Neuroblastoma 5.5 3.9 13.5 2.1 4.0 1.9 5.9 1.2 0.8 6.2 3.2 3.4
V. Retinoblastoma 21.8 5.1 8.0 5.2 9.7 1.4 4.1 7.1 6.6 5.9 4.8 5.5
VI. Renal tumors 5.2 5.4 10.1 5.0 10.8 2.4 5.7 3.3 6.6 4.1 4.8 5.2
+ Nephroblastoma 5.2 5.3 10.1 5.0 10.8 2.4 5.7 3.3 6.6 4.1 4.8 5.2
VII. Hepatic tumors 4.5 3.5 0.0 1.5 1.4 2.1 1.8 11.3 1.1 2.1 2.2 2.5
+ Hepatoblastoma 3.3 3.2 0.0 1.3 1.4 2.1 1.8 11.3 1.1 2.1 2.0 2.3
VIII. Bone tumors 12.2 6.1 9.8 6.1 8.3 8.1 3.0 5.9 2.6 7.5 6.7 6.3
+ Osteosarcomas 9.9 4.2 6.2 4.6 4.6 7.7 2.4 3.6 1.8 3.7 5.0 4.7
IX. Soft tissue sarcomas 14.0 7.1 9.3 6.1 9.7 5.7 8.2 6.1 4.0 3.8 6.6 6.8
+ Rhabdomyosarcomas 6.7 4.3 1.3 3.8 5.4 3.7 7.0 2.4 4.0 1.8 4.0 4.2
+ Fibrosarcomas 5.7 1.6 1.3 1.1 2.0 0.0 0.6 0.0 0.0 0.0 1.1 1.1
X. Germ cell tumors 9.7 7.7 2.3 9.6 6.5 3.0 8.2 8.3 8.0 10.6 7.6 7.9
+ Malignant gonadal 6.2 6.0 2.3 7.1 2.8 1.2 5.9 5.0 3.4 8.9 5.3 5.5
XI. Carcinomas 5.9 0.9 2.8 0.9 2.3 0.4 1.2 0.0 0.0 0.0 1.1 1.0
TOTAL 203.5 126.4 173.5 117.3 154.3 83.6 103.0 150.7 114.3 101.8 119.2 121.5
1Rates per 1,000,000 child/years; 2Only the incidence of principal subgroups are presented; 363 cases of Histiocytosis were not included; IMSS, 
Instituto Mexicano del Seguro Social, n, Number of cases; CNS, Central Nervous System; IIET, Intracraneal and Intraespinal Embryonal Tumors; 
STS, Soft Tissue Sarcomas; CHIS, Chiapas; MC, Mexico City; GRO, Guerrero; MS, Mexico State; MOR, Morelos; JAL, Jalisco; NL, Nuevo León; PUE, 
Puebla; VER, Veracurz; YUC, Yucatán.BMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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pathologists of the Pediatric Hospital of Medical Center
"Siglo XXI" have commented on their impression that
cases of the rarest types of cancer in children were found
in Chiapas (personal communication). Such was the case
in the present work as, in Chiapas, both the frequency
(3.5%) and the incidence (5.9 per 1,000,000 children/
year) of carcinomas (usually the least frequent among
cases of childhood cancers) were found not only to be
higher than those of any of the other ten jurisdictions, but
also to be one of the highest reported in the world
[5,6,11].
We corroborated the foregoing by calculating the ratio of
the observed rate to the expected rate for each Jurisdiction
studied [22]. As was mentioned in Methods, we found
that, in nine jurisdictions, the ratio of the observed and
the expected rates was equal to, or greater than, 0.90; only
in Jalisco, was it 0.71. With these data, we corroborated
that we had an underestimation of the registered cases in
Jalisco and that the incidence in Chiapas is one of the
highest in the world [11]. The finding that one state had
such a distinct profile of cases of childhood cancer under-
scores the necessity of developing analytical studies with
the aim of understanding the risk factors that this pediat-
ric population has in developing cancer.
Other indications of the validity of the data presented
here were that both the frequency and the incidence of the
principal types of cancer, the profile of the age at presen-
tation (greatest incidence in those <5 years of age, falling
off at 5–9 years, and rising again at 10–14 years), and the
M/F ratio were consistent with the values reported for
other countries [3,5-8,11]. From the foregoing, we con-
sider that, based on the hospitals selected for the study
and on the manner in which the data were collected and
the results obtained, our data on the frequency and inci-
dence of childhood cancer in the jurisdictions in this
study (with the possible exception of Jalisco) have the
greatest precision when compared to data previously
reported [14-16]. However, we must continue to perform
a quality registry of the cases of cancer in the jurisdictions
studied, because when a great number of cases, especially
well-registered cases, are used for the calculations, the pre-
cision of the resulting incidence in the studied population
will be increased.
Although IMSS provides medical attention to 50% of the
Mexican population (thus, to approximately 50% of the
population of Mexican children), only workers and their
family members are covered. Because the remainder of the
population, 10% of which are considered to live in
extreme poverty, are attended by other institutions (Min-
istry of Health, the Armed Forces, Instituto de Seguridad
Social al Servicio de los Trabajadores del Estado), it will be
necessary to perform studies specifically with these popu-
lations in order to know the incidence of cancer in Mexi-
can children.
Table 4: Average annual and age-standardized incidence per period1 of five principal malignant neoplasms in children served by IMSS 
and residing in the jurisdictions of Nuevo León, and Jalisco
Diagnostic group Age group (years) Sex
<1 1–4 5–9 10–14 M F AAI AAS M/F2
Nuevo León 98-00 (cases) N = 5 n = 85 n = 40 n = 47 n = 96 n = 81 n = 177 n = 177 96/81
1. Leucemias 7.7 57.4 25.3 20.4 32.7 31.8 32.3 32.5 1.1
2. CNS tumors 7.7 23.0 11.8 26.5 21.5 16.5 19.0 19.2 1.4
3. Lymphomas 7.7 13.4 10.1 16.3 13.5 11.8 12.7 12.7 1.2
- Hodgkin lymphomas 0.0 5.7 3.4 10.2 4.5 7.1 5.8 5.8 0.7
- Non Hodgkin lymphomas 7.7 7.7 6.8 6.1 9.0 4.7 6.9 6.9 2.0
4. Soft-tissue sarcomas 0.0 19.1 3.4 4.1 10.2 5.9 8.1 8.2 1.8
5. Germ cell tumors 0.0 11.5 3.4 12.2 5.6 10.6 8.1 8.2 0.6
Total 38.6 162.7 67.5 95.9 108.4 95.4 102.0 103.0 1.2
Jalisco 98-00 (cases) N = 11 n = 70 N = 51 n = 59 n = 110 n = 81 n = 191 n = 191 110/81
1. Leucemias 14.4 67.0 31.3 36.2 52.5 30.9 41.9 42.5 1.8
2. CNS tumors 21.6 7.6 7.5 8.4 10.2 7.1 8.6 8.9 1.5
3. Bone Tumors 0.0 0.0 12.5 13.9 4.2 13.2 8.6 8.1 0.3
4. Lymphomas 0.0 7.6 5.0 11.1 8.5 6.2 7.3 7.2 1.4
- Hodgkin lymphomas 0.0 1.5 2.5 4.2 3.4 1.8 2.6 2.5 2.0
- Non Hodgkin lymphomas 0.0 6.1 2.5 7.0 5.1 4.4 4.8 4.7 1.2
5. Soft-tissue sarcomas 7.2 7.6 2.5 7.0 6.8 4.4 5.6 5.7 1.6
Total 79.2 106.7 63.8 82.1 93.2 71.5 82.6 86.3 1.4
1Rates per 1,000,000 child/years; 2M/F = Ratio male/female; AAI = Average annual incidence; AAS = Average annual age-standardized incidence; 
CNS = Central Nervous System.BMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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Table 5: Average annual and age-standardized incidence per period1 of five principal malignant neoplasms in children served by IMSS 
and residing in the jurisdictions of Mexico City, State of Mexico, Morelos, and Puebla
Age group (years) Sex
Diagnostic group <1 1–4 5–9 10–14 M F AAI AAS M/F2
México City 92-02 (cases) n = 44 n = 266 n = 220 n = 204 n = 392 n = 342 n = 734 n = 734 392/342
1. Leukemias 37.3 78.9 50.7 40.4 58.2 49.9 54.1 55.4 1.2
2. CNS tumors 10.6 18.2 15.6 17.3 16.2 16.9 16.5 16.5 1.0
3. Lymphomas 0.0 13.1 16.1 17.8 20.8 8.6 14.8 14.4 2.5
- Hodgkin lymphomas 0.0 1.3 2.9 7.9 5.9 1.7 3.9 3.6 3.6
- Non Hodgkin lymphomas 0.0 11.9 13.2 10.0 14.9 6.9 11.0 10.8 2.3
4. Germ cell tumors 18.6 7.5 2.4 11.0 6.6 8.6 7.6 7.7 0.8
5. Soft-tissue Sarcomas 5.3 10.0 7.3 4.2 4.6 9.3 6.9 7.1 0.5
Total 117.1 166.6 107.4 106.9 129.6 117.7 123.8 126.3 1.1
State of México 96-02 (cases) n = 44 n = 301 n = 234 n = 259 n = 446 n = 392 n = 838 n = 838 446/392
1. Leucemias 23.7 84.1 52.8 52.6 63.6 54.9 59.3 60.2 1.2
2. CNS tumors 2.2 12.2 9.1 11.7 9.7 10.9 10.3 10.3 0.9
3. Lymphomas 0.0 6.1 15.0 10.9 13.8 6.7 10.3 9.9 2.1
- Hodgkin lymphomas 0.0 1.5 7.1 6.5 5.9 3.9 4.9 4.6 1.6
- Non Hodgkin lymphomas 0.0 4.6 7.9 4.4 7.9 2.8 5.4 5.3 2.9
4. Germ cell tumors 21.6 12.7 4.3 9.1 8.9 9.5 9.2 9.6 1.0
5. Bone Tumors 0.0 1.5 3.2 15.7 4.3 8.7 6.5 6.1 0.5
Total 94.9 153.4 92.2 112.7 120.7 109.8 115.4 117.3 1.1
Morelos 96-02 (cases) n = 9 n = 45 n = 32 n = 31 n = 60 n = 57 n = 117 n = 117 60/57
1. Leucemias 0.0 82.2 73.9 60.2 64.2 72.5 68.3 66.8 0.9
2. Lymphomas 0.0 27.4 14.1 20.1 32.1 5.2 19.0 18.9 6.5
- Hodgkin lymphomas 0.0 4.6 3.5 4.0 7.4 0.0 3.8 3.7 -
- Non Hodgkin lymphomas 0.0 22.8 10.6 16.0 24.7 5.2 15.2 15.1 5.0
3. CNS tumors 52.2 22.8 7.0 8.0 9.9 18.1 13.9 15.7 0.6
4. Renal Tumors 52.0 18.3 3.5 0.0 9.9 7.8 8.9 10.8 1.3
5. Bone Tumors 0.0 4.6 7.0 16.0 4.9 12.9 8.9 8.3 0.4
Total 235.1 205.5 112.6 124.4 148.2 147.7 148.0 154.3 1.1
Puebla 98-00 (cases) n = 11 n = 29 n = 34 n = 40 n = 62 n = 52 n = 114 n = 114 62/52
1. Leukemias 82.0 86.8 60.4 69.4 55.4 88.4 71.6 72.9 0.6
2. Lymphomas 0.0 9.1 24.9 40.8 37.8 10.4 24.3 22.7 3.8
- Hodgkin lymphomas 0.0 4.6 14.2 20.4 20.1 5.2 12.8 11.9 4.0
- Non Hodgkin lymphomas 0.0 4.6 10.7 20.4 17.6 5.2 11.5 10.8 3.5
3. CNS tumors 0.0 9.1 17.8 12.3 12.6 13.0 12.8 12.1 0.5
4. Hepatic Tumors 109.3 9.1 0.0 0.0 12.6 2.6 7.7 11.3 0.2
5. Germ cell tumors 27.3 4.6 0.0 16.3 2.5 13.0 7.7 8.3 0.2
Total 300.7 132.4 120.7 163.4 156.0 135.2 145.8 150.7 1.2
1Rates per 1,000,000 child/years; 2M/F = Ratio male/female; AAI = Average annual incidence; AAS = Average annual incidence standardized; CNS = 
Central Nervous System.BMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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Table 6: Average annual and age-standardized incidence per period1 of five principal malignant neoplasms in children served by IMSS 
and residing in the jurisdictions of Guerrero, Veracruz, Chiapas, and Yucatán
Age group (years) Sex
Diagnostic group <1 1–4 5–9 10–14 M F AAI AAS M/F2
Guerrero 96-02 (cases) N = 7 n = 51 N = 29 n = 38 n = 70 n = 55 n = 125 n = 125 70/55
1. Leukemias 26.1 82.3 31.9 72.2 66.0 48.7 57.4 58.8 1.4
2. CNS tumors 0.0 38.8 28.3 31.6 15.8 46.0 30.7 30.3 0.4
3. Lymphomas 0.0 48.4 17.7 27.1 44.9 10.8 28.0 28.6 4.3
- Hodgkin lymphomas 0.0 0.0 10.6 18.0 10.6 8.1 9.3 8.6 1.3
- Non Hodgkin lymphomas 0.0 48.4 7.1 9.0 34.3 2.7 18.7 19.9 0.9
4. Bone Tumors 0.0 0.0 14.2 18.0 18.5 2.7 10.7 9.8 6.9
5. Soft-tissue sarcomas 52.1 0.0 0.0 18.0 10.6 5.4 8.0 9.3 2.0
Total 182.5 247.0 102.7 171.4 184.7 148.7 166.9 173.5 1.3
Veracruz 98-02 (cases) n = 2 n = 46 N = 44 n = 33 n = 66 n = 59 n = 125 n = 125 66/59
1. Leukemias 40.9 67.3 57.4 42.2 53.0 55.1 54.0 54.8 1.0
2. CNS tumors 0.0 21.3 17.5 15.8 17.7 16.5 17.1 16.8 1.1
3. Lymphomas 0.0 3.5 22.4 15.8 21.2 7.3 14.4 12.9 3.0
- Hodgkin lymphomas 0.0 3.5 10.0 10.6 12.4 3.7 8.1 7.4 3.5
- Non Hodgkin lymphomas 0.0 0.0 12.5 5.3 8.8 3.7 6.3 5.6 2.5
4. Germ cell tumors 0.0 10.6 10.0 5.3 5.3 11.0 8.1 8.0 0.5
5. Retinoblastoma 0.0 21.3 0.0 0.0 3.5 7.3 5.4 6.6 0.5
Total 40.9 163.0 109.7 87.1 116.5 108.3 112.5 114.3 1.1
Chiapas 96-02 (cases) n = 12 n = 49 N = 39 n = 43 n = 73 n = 70 n = 143 n = 143 73/70
1. Leukemias 55.1 96.6 62.4 68.5 69.2 76.2 72.7 74.2 0.9
2. CNS tumors 55.1 59.0 11.0 20.1 24.0 32.6 28.3 31.9 0.7
3. Retinoblastoma 137.8 32.2 3.7 0.0 13.3 19.0 16.1 21.8 0.7
4. Lymphomas 0.0 10.7 29.4 20.1 29.3 10.9 20.2 18.6 2.7
- Hodgkin lymphomas 0.0 10.7 7.3 8.1 10.7 5.4 8.1 8.0 2.0
- Non Hodgkin lymphomas 0.0 0.0 22.0 12.1 18.6 5.4 12.1 10.6 3.4
5. Soft-tissue sarcomas 0.0 37.6 0.0 8.1 8.0 16.3 12.1 14.0 0.5
Total 330.7 263.0 143.2 173.2 194.4 190.4 192.4 203.5 1.0
Yucatán 98-00 (cases) n = 3 n = 24 N = 15 n = 9 n = 24 n = 27 n = 51 n = 51 24/27
1. Leukemias 72.7 73.8 49.5 19.4 42.1 55.6 48.8 50.1 0.8
2. Germ cell tumors 36.4 13.4 5.5 6.5 11.5 7.9 9.8 10.6 1.5
3. CNS tumors 0.0 13.4 16.5 0.0 11.5 7.9 9.8 9.5 1.5
4. Bone Tumors 0.0 0.0 0.0 25.9 0.0 15.9 7.8 7.5 -
5. Neuroblastoma 0.0 20.1 0.0 0.0 0.0 11.9 5.9 6.2 -
Total 109.1 161.0 82.5 58.2 91.9 107.3 99.5 101.8 0.9
1Rates per 1,000,000 child/years; 2M/F = Ratio male/female; AAI = Average annual incidence; AAS = Average annual age-standardized incidence; 
CNS = Central Nervous System.BMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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It is interesting that no unique pattern for the principal
groups of cancer (leukemias, CNS tumors, and lympho-
mas) was found; in the present study, the North Ameri-
can-European pattern was found in six of the ten
jurisdictions studied, with the data from Nuevo Leon
most notably demonstrating this pattern. Data from
Morelos and Puebla clearly showed the Latin-American
pattern. Jalisco, Chiapas, and Yucatán have another pat-
tern. From these data, the question arises as to whether the
different patterns in the presentation of different cancer
groups were due to the use of a detailed cancer registry, or
to distinct or changing risk factors, or to a combination of
the two. It should be noted that, in the present study, the
collection of data was prolective; there is no doubt that
the collection was more detailed and more precise com-
pared to the data in previous studies in which the collec-
tion was retrospective [14-16].
However, we may also consider the possibility that there
may be distinct risk factors encountered in the jurisdic-
tions studied, because the jurisdiction located in the north
(Nuevo León); the west (Jalisco); the center (Mexico City,
State of Mexico, Morelos, Puebla); or the south or south-
east of Mexico (Guerrero, Veracruz, Chiapas, Yucatán)
generally have different patterns of disease and different
socio-economic conditions. Those jurisdictions in the
North have a pathology similar to that of North American
children; for those in the Western, Center, and most espe-
cially, in the South, the principal pathologies are the infec-
tious type and nutritional deficiencies. Similarly, the
states in the north and in the center of the country have
better socio-economic conditions compared to those of
the states in the South, the poorest being Guerrero, Chia-
pas [27,28]. This leads to the supposition that distinct risk
factors may act on the presentation of the different can-
cers. It would, therefore, be interesting to carry out analyt-
ical studies to establish what the possible risk factors are
and to determine if the disease patterns are due to the
improved registry of cases, to these distinct risk factors, or
to both.
In regard to the predominant neoplasms, leukemias, HD,
neuroblastoma, retinoblastoma, and germ cell tumors
deserve special comment. For leukemias, in general, the
children in this study had some of the highest frequencies
of leukemias in the world (seven jurisdictions having a
frequency >40%) and, consequently, also had some of the
highest incidence (eight jurisdictions with an incidence
>50 per 1,000,000 children/year), with values compara-
ble to those of children in Canada, of Hispanic and Black
children in Los Angeles, and of children in Costa Rica and
Ecuador. For other continents, the data are similar for the
children of Denmark, Australia, Hong Kong, and Singa-
pore [11]. These data underscore the necessity of develop-
ing analytical studies with the objective of determining
and studying possible risk factors. In particular, due to
how widespread it is in the Mexican population, tobacco
smoking would be an appropriate choice to study in rela-
tion to the prevalence of leukemia. In a study on children
with Down's Syndrome who reside in Mexico City, it has
been shown that if the father smokes while the mother is
pregnant, the child has a higher risk of developing leuke-
mia [29].
For HL, the lowest incidence was found in Yucatán, and
Jalisco (1.9 and 2.5 per 1,000,000 children/year, respec-
tively); in the remaining states, the incidence ranged
between 3.6 per 1,000,000 children/year (Mexico City)
and 11.9 per 1,000,000 children/year (Puebla), values
similar to those for children in North America and Europe
[11]. It is noteworthy that, in comparison to previous
reports for the children residing in Mexico City, not only
the frequency (10.7, 9.0, and 3.1% in 1991, 1992–1993,
and 1996–2002, respectively) but also the incidence (6.5,
7.7, and 3.6 per 1,000,000 children/year for these same
time periods) apparently fell spontaneously [14,15,26].
This phenomenon is consistent with that mentioned by
Linet et al. (1999) for children in the United States [4].
Because the Epstein-Barr virus has been mentioned as a
possible causal agent [30] in the etiology of the HL, it will
be interesting to perform an ecological study to determine
if any correlation exists between the use of antivirals,
which at present are used indiscriminately throughout
much of Mexico, and the incidence of HL. Data from such
a study would either prove or disprove the hypothesis that
the apparently spontaneous fall in HL in the children of
Mexico City may be due to the excessive use of antivirals
[26].
It is interesting that, in developed countries, the frequency
of neuroblastoma is 5 to 10% and the incidence is 8.0 to
15.0 per 1,000,000 children/year, values that contrast
with those in developing countries (frequency, 3 to 5%;
incidence, is 3.5 to 9.3 per 1,000,000 children/year) [11].
The data obtained in our study are similar to those from
the developing countries, with eight jurisdictions having a
frequency <5% and seven jurisdictions having an inci-
dence less than 5 per 1,000,000 children/year. In coun-
tries such as Japan, where screening tests are carried out in
an attempt to achieve an early diagnosis, it has been
shown that, of the cases detected by this method, 59%
had spontaneous regression [31]. It is likely that, in Mex-
ico and in countries having similar socio-economic devel-
opment, there really is a lower frequency of cases of
neuroblastoma, or whether there are cases that are not
diagnosed but that spontaneously regress [32].
Between 20 to 40% of retinoblastoma, an embryonic
tumor, may have a hereditary component [33]. It has been
shown that not only the frequency but also the incidenceBMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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of retinoblastoma is higher in developing countries than
in developed countries [3-8,11]. These data are reflected
in the present study, in that the incidence in the jurisdic-
tions in the south of Mexico, areas than are poorer than
those in the north of the country [28], had higher inci-
dence. Corroborating the results of previous studies car-
ried out by our group, the present data showed that
Chiapas in the south of Mexico had one of the highest
reported frequencies of retinoblastoma [16,25,26] and, in
addition, had the highest incidence (21.8 per 1,000,000
children/year). Also, the data are consistent with a recent
study carried out in a population in the south of Mexico,
where reduction of the mother's intake of vegetables and
fruits during the pregnancy increased the risk of devel-
oped sporadic retinoblastoma in their children [34].
In our study, germ cell tumors had a frequency and inci-
dence that were slightly greater than the values in the
international literature, in which both the frequency (3.0
to 6.8%) and the incidence (2.5 to 9.6 per 1,000,000 chil-
dren/year) are generally higher in Asian countries [11].
With the exception of Guerrero, the frequencies in the
jurisdictions ranged between 3.7 and 9.8% and the inci-
dence between 2.3 and 10.6 per 1,000,000 children/year.
Worldwide, tumors of the gonads are the most frequently
found (40 to 50%) of the germ cells tumors, whereas in
our data, although they were the most frequent, the pro-
portion was higher (43.2 to 100%). However, because the
highest frequency and incidence was found in Yucatán,
the jurisdiction with the fewest cases in the study, this fre-
quency may be random. Therefore, it will be necessary to
perform studies with a greater number of cases in order to
confirm these findings.
A Registry of Childhood Cancer is extremely important
means of assessing both the frequency and the incidence
of neoplasms in the pediatric population, values that are
not known in any great detail in Mexico at present.
Knowledge of the frequency and the incidence of child-
hood cancer have other very valuable uses:
1) In the clinical setting, knowing the frequency of dis-
eases serves to establish the pretest probability that a
patient has upon arrival at the hospital. Such probability
increases or decreases depending on the symptoms pre-
sented, on the sensitivity and specificity of the test(s)
requested, and on the result (positive or negative) of such
test(s) [35]. From the present data, for a child who resides
in Mexico City and for whom the parents sought medical
attention or who was referred to the tertiary care pediatric
hospital upon suspicion of cancer, the pretest probability
(without taking into account the child's symptoms) for
having a leukemia is 43.7%; a lymphoma, 12.0%; or a
CNS tumor, 13.4% (Table 2). This shows the importance
of learning the frequency of the different types of cancer
(or, for that matter, of illnesses in general) that are present
in Mexican children.
2) Knowledge of the frequency and incidence of child-
hood cancer can aid in the planning of future health serv-
ices, in that it provides a basis not only for estimating the
personnel (physicians, nurses, laboratory technicians,
etc.) necessary to provide medical care to these children,
but also for allocating the equipment, pharmaceuticals,
and laboratory consumables necessary for the ideal treat-
ment of children with cancer [36]. For example, when
planning the medical attention needed to treat childhood
cancer in Mexico City, it should be taken into account that
the data suggest that the great majority (43.7%) of these
children will have some type of leukemia and that, yearly,
55.4 cases per million children residing in this jurisdiction
may be expected (Table 3). Similar predictions may be
made for the children in the other jurisdictions studied.
From the foregoing, it is imperative that, in Mexico, a
definitive registry of childhood cancer be established in all
hospitals that treat children with cancer. This should be
done ex profeso for cases of cancer in the pediatric popula-
tion, because cancer in children is distinct from that in
adults. The coding and grouping are quite different;
hence, personnel who work on these registries must have
the specialized training required to maintain the quality
of the registry [37,38]. Such a Cancer Registry would be
the first step towards a better understanding of the epide-
miology of cancer in the pediatric population and, in the
future, towards the prevention and control of cancer, as
has been seen in countries that have established national
programs for the registry of cancer [39].
We think that to be most effective, when establishing a
Registry of Childhood Cancers, the registering of cases of
pediatric cancer be made mandatory. In general, of the
total pediatric population (supposing an average inci-
dence of 130 per 1,000,000 children/year), 4,000 to 4,500
cases of childhood cancer are presented annually in Mex-
ico. Therefore, IMSS each year will treat approximately
between 2,000 and 2250 cases that could well be reported
to, and included in, the Registry of Childhood Cancers of
the hospitals of the Medical Centers-IMSS. Thus, these
children and the society in general would reap the benefits
obtained when cases of childhood cancer are properly reg-
istered.
Conclusion
We conclude that the North American-European pattern
of cancer was the principal one encountered and that the
general incidence was within the range reported in the
world literature. The incidence of leukemias was high in
the majority of the jurisdictions studied, whereas the inci-
dence of neuroblastoma was low. The highest incidence ofBMC Cancer 2007, 7:68 http://www.biomedcentral.com/1471-2407/7/68
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retinoblastoma was found in Chiapas, one of the poorest
jurisdictions. In general but particularly in two jurisdic-
tions (Yucatán and Chiapas), it will be necessary to
develop studies concerning the causes of cancer in chil-
dren. We think that a detailed and mandatory Registry of
Childhood Cancer must be established in all hospitals
that provide medical attention to these children. We con-
sider that this would be a great step in learning of inci-
dence of these diseases in Mexico.
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